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Anti-ﬁbrotic therapeuticsFibrosis is a major clinical problem associated with as many as 45% of all natural deaths in developed nations.
It can affect all organs and accumulating evidence indicates that ﬁbrogenesis is not merely a bystander prod-
uct of injury, but is a central pathological problem directly contributing to loss of organ function. In the ma-
jority of clinical cases, ﬁbrogenesis is strongly associated with the recruitment of leukocytes, even in the
absence of infection. Although chronic infections are a signiﬁcant cause of ﬁbrogenesis, in most cases ﬁbrotic
disease occurs in the context of sterile injury, such as microvascular disease, toxic epithelial injury or diabetes
mellitus. Fibrogenesis is a direct consequence of the activation of extensive, and previously poorly appreciat-
ed, populations of mesenchymal cells in our organs which are either wrapped around capillaries and known
as ‘pericytes’, or embedded in interstitial spaces between cell structures and known as resident ‘ﬁbroblasts’.
Recent fate-mapping and complementary studies in several organs indicate that these cells are the precursors
of the scar-forming myoﬁbroblasts that appear in our organs in response to injury. Here we will review the
literature supporting a central role for these cells in ﬁbrogenesis, and highlight some of the critical cell to
cell interactions that are necessary for the initiation and continuation of the ﬁbrogenic process. This article
is part of a Special Issue entitled: Fibrosis: Translation of basic research to human disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Repair of damaged tissues after chronic or repetitive injury is of crit-
ical importance to survival. The repair process typically involves two
distinct steps: a regenerative phase, where injured cells are replaced
by cells of the same type, leaving no lasting evidence of damage; and
a phase of ﬁbrosis (also known as scarring) where connective tissue re-
places normal, parenchymal tissue [1]. Although initially beneﬁcial, a
failure of the normal wound healing response to terminate results in
chronic disease, contributing to morbidity and mortality for millions
of people worldwide which, in early stages, may be asymptomatic. In
theUSA, it has been estimated that organﬁbrosis is a contributory factor
in as many as 45% of all natural deaths [1].
Despite having distinct etiological and clinical manifestations de-
pending on the injured tissue, ﬁbrosis is a common pathological
response: in all cases it is characterized by the sustained production of
growth factors, proteolytic enzymes, angiogenic factors, and ﬁbrogenic: Translation of basic research
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l rights reserved.cytokines, leading to the progressive and excessive production, deposi-
tion, and contraction of ﬁbrillar extracellular matrix (ECM) compo-
nents, a process of matrix remodeling. This production of ﬁbrillar ECM
may be a tissue response to limit organ damage, or to maintain tissue
architecture. However, in cases where ﬁbrosis does not cease and re-
solve, the accumulation and contraction of ﬁbrillar ECM results in the
distortion of tissue architecture. This is a major problem not only for or-
gans thatmove (e.g. heart and lungs) but also for relatively static organs
(e.g. kidney and liver). An expansion and stiffening of the interstitium
that surrounds parenchymal units (for example, the nephron) disrupts
physiological function and capillary microperfusion. In addition, the
cells responsible for ﬁbrillar ECM deposition, known as myoﬁbroblasts,
and the associated inﬂammatory leukocytes, directly damage tissues in-
cluding capillaries and thereby promote organ failure.
Fibroproliferative disease (i.e. ﬁbrosis and proliferation of ﬁbrogenic
cells)may affect tissues in any solid organ, including skin, kidneys,mus-
cle, lungs, cardiac and vascular system, central nervous system, eyes,
liver, pancreas and intestine. Many of the common diseases in which
ﬁbrogenesis is implicated have few, or no, current therapies and are
managed largely by supportive measures. At this time, there are no
therapeutics targeting the ﬁbrogenic process approved for use by the
US Food and Drug Administration and only a few are licensed in Europe
and Japan. Despite this, the prospects for effective anti-ﬁbrotic therapies
based on targeting key participants in ﬁbrogenic cascades are excellent,
and urgently required.
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genesis, known as the myoﬁbroblast (or sometimes disease-associated
ﬁbroblast) and its precursors (Fig. 1). We will ﬁrst describe how
inﬂammatory factors, and damage to local parenchymal cells, potenti-
ate its activation. Then, we will discuss research from several distinct
experimental models that have provided evidence on the origin of
myoﬁbroblasts duringﬁbrogenesis. Finally, wewill discuss potential av-
enues of therapy arising from this research.
2. Relationship between inﬂammation and ﬁbrosis
Acute and chronic inﬂammatory reactions play an important part
in triggering the activation of myoﬁbroblasts in many different organs
(Fig. 1). Acute inﬂammation is a rapid response to injurious agents
while chronic inﬂammation is a process of prolonged duration in
which the inﬂammatory cascade lasts for weeks or months. In acute
inﬂammation, the exposure of epithelial and/or endothelial cells to
injurious stimuli such as bacteria, toxins, or therapeutically adminis-
tered drugs, activates an inﬂammatory wound-healing response that
can lead to a temporarily excessive deposition of ﬁbrillar ECM compo-
nents in the affected tissues. This excess ECM is thought to largely re-
solve, although contemporary literature suggests even this resolution
may be incomplete in many instances [2,3]. In contrast, pathogenic ﬁ-
brosis results from persistent inﬂammatory triggers, and is a patho-
logical mechanism during which inﬂammation, tissue destruction
and repair processes occur simultaneously.
2.1. Activation of the coagulation cascade
Wound-healing responses start directly after injury with the forma-
tion of a blood clot that initiates a cascade of events. It involves complexPericyte
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Fig. 1. Overview of wound healing: tissue regeneration or ﬁbrosis. Epithelial and/or endoth
anti-ﬁbrinolytic-coagulation cascade, which triggers blood clot formation. This is followed by an
epithelial and/or endothelial can also directly activate the pericyte–myoﬁbroblast transition. Th
ﬁbrillar ECM components. Collagen ﬁbers become organized, blood vessels are restored to nor
regenerate the damaged tissue. However, persistent inﬂammation can lead to chronic myoﬁbr
ﬁbrosis.interactions between coagulation, inﬂammation, angiogenesis, and cel-
lularmigration and proliferation [4].When epithelial and/or endothelial
cells of an organ are damaged, they release inﬂammatory mediators
that initiate an anti-ﬁbrinolytic coagulation cascade within the vascula-
ture, resulting in the formation of both blood clots and a provisional
ECM. Blood-clots release thrombin, a potent inducer of platelet degran-
ulation. Platelet degranulation promotes vasodilation, an increase in
blood vessel permeability, and the production of ECM-degrading en-
zymes (known asmatrixmetalloproteinases,MMPs); all of these events
promote the inﬂammatory responses by allowing the recruitment of
immune and non-immune cells.
2.2. Recruitment of the innate myeloid cells
Neutrophils and macrophages are the ﬁrst cell types recruited at
the site of injury. Activatedmacrophages and neutrophils phagocytize
foreign material and bacteria, also removing damaged cells and stro-
mal debris. They also release cytokines and chemokines, which are
mitogenic and chemotactic for adaptative immune cells, thus ampli-
fying the wound-healing response. As a combined consequence of
all these factors, wound healing can only occur after inﬁltrating in-
ﬂammatory cells are brought under physiological control.
2.3. Activation of the adaptative immune cells
Concomitantly, lymphocytes become activated and secrete vari-
ous wound-healing/pro-ﬁbrotic cytokines and growth factors, includ-
ing platelet-derived growth factor (PDGF), transforming growth
factor 1 β (TGFβ-1) and interleukin (IL)-13. These mediators allow
local mesenchymal cells to transform into α-smooth muscle actin
(α-SMA)-expressing and ECM-producing myoﬁbroblasts. / resident fibroblast/ 
senchymal cell 
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elial damage caused by various insults release inﬂammatory mediators that initiate an
inﬂammatory phase, duringwhich leukocytes are recruited at the site of injury. Damaged
en,myoﬁbroblasts derived from pericytes/residentﬁbroblasts/mesenchymal cells produce
mal, scar tissue is eliminated, and epithelial and/or endothelial cells divide and migrate to
oblast activation and excessive accumulation of ECM components ultimately resulting in
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Once activated, myoﬁbroblasts move into the wound-bed using
the initial ﬁbrin as a scaffold, and begin to proliferate. This promotes
wound contraction, the process in which the edges of the wound mi-
grate towards the center. Myoﬁbroblasts also secrete factors that are
mitogenic and chemotactic for epithelial and/or endothelial cells,
allowing their proliferation and migration and regeneration of the
site of injury.2.5. Persistent activation of myoﬁbroblasts and ﬁbrosis
When inﬂammation becomes chronic, myoﬁbroblasts continuous-
ly synthesize ECM, causing the formation of a ﬁbrotic scar. Conse-
quently, removal of the inﬂammatory trigger is mandatory to stop
the progression of tissue remodeling and allow the normal tissue ar-
chitecture to be restored after injury. Treatment with drugs (antivi-
rals, antibiotics, antifungals) may be effective where infectious
agents are implicated, but knowledge of the speciﬁc inﬂammatory
stimulus is a prerequisite [5]. In many ﬁbrotic diseases, the tissue-
damaging signal is either unknown or cannot be easily eliminated.
In this case, identifying the key mediators of the innate and adaptive
immunity as potential targets is one method for stopping the progres-
sion of ﬁbrosis.
Disease-initiating inﬂammatory and ischemic events converge on
the appearance and activation of myoﬁbroblasts; because of this, ﬁ-
brosis research over the past 15 years has focused on the question
of their cellular origin, the mechanism of their activation and the
molecular/cellular pathways by which they can be deactivated.3. Myoﬁbroblasts produce the pathogenic ﬁbrillar ECM in ﬁbrosis
Although a number of cell types have the potential to produce and
secrete ECM, including epithelial cells, endothelial cells and leukocytes,
it is myoﬁbroblasts that produce the pathogenic, ﬁbrillar collagenous
matrix observed in all forms of ﬁbrosis. Especially, myoﬁbroblasts de-
posit collagen types I and III, found in ﬁbrotic organs, but also collagen
type IV, glycosaminoglycans, heparan sulfate proteoglycans, and glyco-
proteins such as laminins and ﬁbronectin.
Myoﬁbroblasts, originally termed “wound ﬁbroblasts,” were ﬁrst
deﬁned by electron microscopy studies of skin wounding in 1972,
and characterized by abundant rough endoplasmic reticulum, ellipti-
cal and speckled nuclei, a spindle-shaped cell body, and the absence
of lysosomes [6,7]. They are deﬁned biochemically by their expression
of the intermediate ﬁlaments desmin, vimentin, and the contractile
protein αSMA (in humans, one of six currently identiﬁed proteins in
the actin family). αSMA is also found in vascular smooth muscle
cells (vSMCs) and other cells of mesenchymal origin [8]. Contempo-
rary studies distinguish ‘disease-associated ﬁbroblasts’ from
myoﬁbroblasts by the expression of αSMA, but depending on the spe-
cies, the organ studied, and the degree of cellular activation, these
overlapping names represent the same type of cell. Myoﬁbroblasts
are also characterized morphologically by the formation of stress ﬁ-
bers, and physiologically, by their ability to contract tissues. Indeed,
αSMA incorporation into the actin–myosin machinery is frequently
observed as a cell becomes more contractile [9,10]. This is an impor-
tant characteristic for a cell that undergoes contraction, increasing
isometric tension within the tissue [10–13].
In liver and kidney in particular, over-activity of the interstitial
myoﬁbroblast is the convergent point for almost all chronic diseases.
Other pathologies in which myoﬁbroblast activity is a signiﬁcant fac-
tor include myocardial infarction, chronic obstructive pulmonary dis-
ease, diabetes mellitus, chronic colitis, atherosclerosis, stroke, and
skin diseases such as scleroderma.4. Resident mesenchymal precursors are the major source of
myoﬁbroblasts across multiple organs
4.1. Resident mesenchymal cells
It is well-established that interstitial ﬁbroblasts can proliferate in re-
sponse to injury, and can activate to becomemyoﬁbroblasts [14–17]. As
part of this process, interstitial ﬁbroblasts reduce their expression of
5′-nucleotidase and increase expression ofαSMA [14]. Interstitial ﬁbro-
blasts, perivascular ﬁbroblasts, pericytes and hepatic stellate cells
(HSCs) are all resident mesenchymal precursors of the myoﬁbroblast:
they are distinguishable from each other only by their tissue location,
a variance in their anatomical connections with endothelial cells, and
a limited specialization of function, such as vitamin A storage in the
case of HSCs [18–26]. When localized to arterioles, the resident mesen-
chymal cells are known as perivascular ﬁbroblasts, and when localized
to capillaries they are known as pericytes. HSCs may be considered a
specialized form of pericyte, whereas interstitial ﬁbroblasts are those
resident mesenchymal cells identiﬁed in the stroma [18,27,28]. Once
pericytes and HSCs have activated and detached from the capillary
bed, they then become indistinguishable from interstitial ﬁbroblasts
that have concomitantly transformed intomyoﬁbroblasts [14,21,29,30].
During development, mesenchyme-derived cells express αSMA
but, unlike myoﬁbroblasts in adult tissue, they are not responsible
for scar formation. Rather, they form the loose connective tissue of
the stroma, regulate angiogenesis, and induce branching morphogen-
esis in the developing epithelium [31]. In some cases, during develop-
ment, mesenchymal to epithelial transdifferentiation (MET) occurs;
the most extensively studied example is the formation of tubular ep-
ithelium in the developing kidney from metanephric mesenchyme
[32,33]. Although the reverse process (EMT) is an important patho-
logical indicator in cancer, and may readily occur in vitro, fate-
tracing studies have demonstrated it is not a contributory factor to
the appearance of myoﬁbroblasts in either liver, lung or renal ﬁbrosis
[19,34–36]. However, as stated below, studies unequivocally show
that the injured epithelium alone can directly trigger ﬁbrogenesis in
many organs, including liver, lung and kidney.
Whereas, during development,mesenchymal cells aremetabolically
active andmigratory, in the adult organ they down-regulate expression
of many genes, includingαSMA, and enter into a relative quiescence. In
this state, they occupy various niches across the entire bodywhere they
may perform a variety of physiological functions, including mainte-
nance of the connective tissue, regulation of immune responses and sta-
bilization of the microvasculature [30,37,38]. However, following acute
or chronic injury, mesenchymal cells are reactivated in mature tissue
and transform to myoﬁbroblasts.
Although the origin of the myoﬁbroblast in ﬁbrosis has been
known to be local to the site of initial injury since at least 1963, it is
only recently with genetic fate-mapping that the precursor to the
myoﬁbroblast can be conclusively demonstrated to be the resident
mesenchymal cell [7,18–20,39,40]. Strong evidence for this has arisen
commensurately from independent studies on the kidney, skin, skel-
etal muscle, lung, liver, and brain.
4.2. Myoﬁbroblast progenitors in the kidney
The fate of pericytes after renal injury was initially determined by
the careful analysis of collagen Iα1 expression patterns and genetic
fate-mapping based on the transcription factor forkhead box D1
(Foxd1) in mice (Figs. 2–3) [19,21]. First, Lin et al. analyzed transgenic
mice in which the promoter for CollIα1 drove expression of GFP
(CollIα1-GFPTg mice) [21]. Pericytes were observed to detach from cap-
illaries, migrate into the interstitium, markedly up-regulate collagen
Iα1 expression, and re-express the chondroitin sulfate proteoglycan
marker NG2 and αSMA in response to injury: morphologically and
biochemically, these pericytes were now indistinguishable from
Fig. 2. Characterization of pericytes in normal human kidney biopsy sample and in Coll-GFPTg mouse kidney cortex. (A) Normal adult human kidney cortex, immunostained for
CollagenIα(1) protein. Note that CollagenIα(1) protein is strongly expressed in glomerular podocytes (arrowheads), and in perivascular cells from capillaries (arrows). (B) Normal
adult Coll-GFPTg kidney cortex, immunostained for GFP. Coll-GFPTg mice express GFP under regulation by the Coll1α1 promoter, so GFP protein expression indicates Coll1α1 tran-
scription. Note that GFP-expressing cells (glomerular podocytes (arrowheads), perivascular cells (arrows)) in Coll-GFPTg mice are the same as Coll1α1-expressing cells in human
kidney cortex. Therefore, Coll-GFPTg mice are faithful reporters of all cells that produce CollagenIα(1) protein in human kidney. (C) Four color-confocal image of the cortex of
the Coll-GFPTg mouse kidney stained for the capillary basement membrane-speciﬁc protein Lamininα4 (red) and the endothelial marker CD31 (white). Note numerous GFP+
cells that lack endothelial, epithelial or leukocyte markers (not shown) that form extensive processes along capillaries. Note direct interactions with endothelial cell bodies (arrows)
and note Coll-GFP+ processes passing through splits in capillary basement membrane (arrowheads).
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and cell-cycle dynamics were consistent with the total number of
myoﬁbroblasts observed during ﬁbrosis. Humphreys et al. generated
Foxd1-Cre;Rosa26 transgenic mice in which mesenchymal cells were
permanently labeled during embryonic development [19] (Fig. 3).
Foxd1 is known to regulate the commitment of undifferentiated meta-
nephric mesenchyme to become mesenchymal cells early in renal de-
velopment, and can thus be used as a marker of mesenchymal origin.
In Foxd1-GCE mice (GCE: GFP-Cre-Estrogen receptor), the GFPCreERT2
fusion protein is only able to recombine genomic DNA at LoxP sites
when in the nucleus; and this can only occur when the endogenous
Foxd1 gene is active (during early embryonic kidney development) or
the estrogen receptor (ER) agonist, tamoxifen, is applied exogenously.
In non-ﬁbrotic kidneys, strong LacZ (galactosidase) expression was
detected in interstitial cells of both the medulla and cortex. These cells
did not express αSMA or endothelial markers, but they were positive
for CD73 (ecto-5′-nucleotidase; marker of mesenchymal lineage) and
PDGFRβ, a pericyte marker. The authors concluded that these cells
were the same as those detected by Lin et al. in CollIα1-GFPTg mice
[19]. These cells increased in number after acute kidney injury and
expressed αSMA. Indeed, almost 100% of αSMA cells in these mice
were also positive for LacZ, strongly suggesting that the majority, if
not all, of the myoﬁbroblasts in the ﬁbrotic kidneys were derived from
Foxd1 progenitors. To increase experimental stringency, another fate-
tracing method was utilized. Tamoxifen (estrogen receptor ligand)
was used to induce activation of LacZ in FoxD1-CreERT2 mice. Applied
on embryonic day 10.5, tamoxifen induced 20% of stromal cells to be-
come LacZ positive. These cells were then traced as becoming 20% of
Foxd1-derived pericytes in the adult kidney. After kidney injury
these pericytes expanded 15-fold and began to strongly express
αSMA; none of the cells expressed αSMA before injury. Strikingly,
this population of LacZ+ cells represented 20% of the total
myoﬁbroblast population, in accordance with the original proportion
of tamoxifen-induced cells.
More recently, Asada et al. have studied renal pericytes from an
earlier developmental time-point [41]. They fate-mapped myelin pro-
tein zero (P0 cells) from the neural crest to metanephric mesenchyme
during embryogenesis. P0 is expressed in migrating neural crest cells
in the early embryonic stages as well as in Schwann cells, which also
originate from neural crest at later stages. The authors demonstrated
that the majority of erythropoietin-producing ﬁbroblasts in the adulthealthy murine kidney derived from P0+ cells that inﬁltrate into
the kidney during embryonic development (from E13.5 onwards).
They also demonstrated, in three different models of renal ﬁbrosis
that, in response to injury, the P0+ ﬁbroblasts lose their ability to
produce erythropoietin and become myoﬁbroblasts. Moreover, ad-
ministration of neuroprotective agents restored the ability of these
cells to produce erythropoietin and attenuated ﬁbrosis. Given that
P0-Cre fate-mapped cells populate around Six2+ progenitor cells
in the developing kidney, and that these cells overlap with the
Foxd1-PDGFR+ cells that have previously been identiﬁed to be im-
portant in the development of renal ﬁbrosis, there is a strong indi-
cation that the Foxd1-derived cells described by Humphreys et al.
are the same cells as those described by Asada et al.
4.3. Myoﬁbroblast progenitors in dermis and skeletal muscle
It is in the skin that the myoﬁbroblast was ﬁrst described: as a
“contractile cellular element” contributing to scar formation following
inﬂammation in dermal wounds [42]. However, it was in later experi-
ments that the origin of myoﬁbroblasts was demonstrated to be local
to damaged tissue [7,39]. As in the kidney, this has recently been con-
ﬁrmed by genetic fate-mapping in skin and skeletal muscle. The en-
zyme A disintegrin and metalloprotease 12 (ADAM12) was used by
Dulauroy et al. to trace cells of the neural crest-derived embryonic mes-
enchyme in murine models [40]. By crossing Adam12-Cre mice to
Cre-dependent Rosa26ﬂoxSTOP-RFP reporter mice, they were able to
label ADAM12+ cells with both red ﬂuorescent protein (RFP) and
green ﬂuorescent protein (GFP), whereas all ADAM12+ progeny cells
were labeledwith RFP only. ADAM12+ cells migrated in early embryo-
genesis to somites, skin, gut and brain, developing into several different
cellular populations. One speciﬁc ADAM12+ group was characterized
by the additional expression of the pericyte marker PDGFRβ on their
cell surface. Through careful observation, these cells were found to lo-
calize within the capillary basement membranes of skeletal muscle
and dermis, wrapping their plasmamembrane processes around endo-
thelial cells. Upon injury, RFP+ cells expanded in number such that by
day 20, post-lesion, the vast majority of αSMA+ myoﬁbroblasts were
progeny of ADAM12+ cells. By speciﬁcally ablating the ADAM12+
population of cells, ﬁbrosis was attenuated in both skeletal muscle
and skin. Moreover, in an updated version of the classic para-biosis
study by Ross et al., Adam12-Cre;RFP reporter mice were surgically
Fig. 3. Results of fate mapping of Foxd1 progenitors in normal adult and injured kidney using the Foxd1-Cre;Rosa26-tdTomatoR mouse. (A) Schema showing the cross of Foxd1-Cre
recombinase allele with TdTomato reporter allele driven by the universal promoters at the Rosa26 locus. Bigenic mice recombine genomic DNA at the Rosa locus only in cells that
have activated the Foxd1 transcription factor gene in nephrogenesis. (B) Combining the Foxd1-Cre and Rosa26-tdTomatoR alleles with Coll-GFPTg in a single mouse indicates that
perivascular cells of the Foxd1 lineage in kidney overlap almost completely with Coll-GFP+ pericytes (arrowheads). Image shows kidney cortex and kidney medulla. Note that vas-
cular smooth muscle cells in arteriole do not express Coll1α1 (arrows). (C) In kidney injury in Foxd1-Cre;Rosa26-tdTomatoR mice (shown here is UUO d7), perivascular ﬁbroblast
and pericyte populations expand. However, now all of the expanded population of interstitial Foxd1-progenitor derived cells co-express αSMA, the marker which deﬁnes these cells
as myoﬁbroblasts.
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confocal microscopy, it was conﬁrmed that all αSMA+ myoﬁ-
broblasts in acutely injured muscle and dermis are derived from
tissue-resident mesenchymal cells, and not recruited from the
bloodstream.
In patients with muscular dystrophies there is an accumulation of
adipocytes and collagen Iα1-producing cells in skeletal muscle; thisprompted two independent groups to address the origin of cells re-
sponsible for ﬁbro/adipogenic inﬁltration into skeletal muscle after
injury. Uezumi et al. and Joe et al. identiﬁed a population of either
SM/C2.6-, PDGFRα+ or Lin-, Sca1+, α7integrin-, PDGFRα+ cells re-
spectively, that are progenitors of both adipocytes and ‘ﬁbrocytes’ in
undamaged and damaged skeletal muscle; they were distinct from
muscle progenitors [43–45]. In addition, using constitutively active
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activation of PDGFRα signaling induced systemic ﬁbrosis, including
that of skeletal muscle [46]. Given that PDGFRα is also commonly
used as a pericyte marker and pericytes have been shown to be pro-
genitor cells for white adipocytes [47], this suggests that ﬁbro/
adipogenic progenitor cells are pericytes that have the capacity to be-
come adipocytes and vice versa.
4.4. Myoﬁbroblast progenitors in the liver
The residentmesenchymal cell of the liver is the HSC; it is analogous
to the pericyte and perivascular ﬁbroblast in other organs. The HSC was
ﬁrst characterized in 1985, and has also been called the Ito cell and the
lipocyte [48]. HSCs are identiﬁable in the healthy organ as vitamin A
storing cells resident in the sub-endothelial space of Disse between en-
dothelial cells and hepatocytes [49]. In accordancewith regulatory roles
in microvasculature for other pericyte-like cells, HSCs have an impor-
tant function in maintaining the fenestrated endothelium of the sinu-
soidal capillary [28]. In the ﬁrst instance by electron microscopy, and
later through sophisticated genetic studies, theHSC has been conﬁrmed
as the main progenitor pool for myoﬁbroblasts during liver ﬁbrosis
[36,48,50].
During the switch from their resident functions (storing vitamin A,
and regulating vascular integrity), HSCs detach from their resident
tissue-beds, and acquire all the hallmarks of myoﬁbroblasts: increased
proliferation, cessation of communication with their cognate cellular
partners (hepatocytes and endothelial cells), single-cell migration, the re-
lease of ﬁbrillar collagenous matrix, and the release of proinﬂammatory
and ﬁbrogenic cytokines such as TGFβ1 and PDGF [51,52]. HSC activation
may also involve the production of endothelin (ET)-1, nitrous-oxide sig-
naling, and activation of the renin–angiotensin system [53–56].
When ﬁrst characterized by Friedman et al. the cultured HSC, or
lipocyte, was calculated as producing over 20 times themass of collagen
(types I, III and IV) than cultured endothelial cells, and over 10 times the
mass of collagen produced by hepatocytes. Although, the observation
by Friedman et al. that “phenotypic resemblance of [lipocytes] to ﬁbro-
blasts supports the hypothesis that lipocytes may be precursors of the
ﬁbroblast-like cells observed in liver injury” [48] was a qualitative
one, a very recent study has shown this to indeed be the case. In carbon
tetrachloride (CCl4) and alcoholicmodels of liver ﬁbrosis, Kisseleva et al.
fate-mapped HSCs with Coll-Cre− and Coll-CreER mice, demonstrating
that these cells go on to become the collagen-producingmyoﬁbroblasts
seen in liver ﬁbrosis [18].
4.5. Myoﬁbroblast progenitors in the central nervous system
It was in the brain that the pericyte was ﬁrst identiﬁed [57]. As with
other tissues, pericytes in the central nervous system (CNS) are neces-
sary for the integrity of microvasculature, namely the blood–brain bar-
rier (BBB) [37,58]. A recent paper has demonstrated that the pericyte is
the major source for myoﬁbroblasts in CNS scar-formation (ﬁbrosis)
[20]. The authors utilized a new marker for CNS pericytes, Glast, in
order to trace the fate of these cells in transgenic mice. It was found
that pericytes form the core of scars in injured CNS tissue, and that
they give rise to stromal cells that produce collagenous ﬁbrils. These
stromal cells still displayed PDGFRβ on their surface, in accordance
with a pericyte origin. The matrix-producing stromal cells were not de-
rived from astrocytes, a cell type previously held to be responsible for
scar-formation. Moreover, this is one of the ﬁrst studies (along with,
for example, Lin et al. [21]) to depict in high-resolution confocal-
microscopy pericytes in the act of detaching from the capillary bed.
5. Pericyte structure and identiﬁcation
As well as being deﬁned by their Foxd1-associated mesenchymal
origins in several organs including skin and kidney, pericytes are atype of mural cell: they are deﬁned as providing trophic and mechan-
ical support to blood vessels [59]. Pericytes, in contrast to vSMCs,
share a basement membrane with endothelial cells and can be in di-
rect contact via extended cell-processes: these are a key morpholog-
ical characteristic of the pericyte. Endothelial cells and pericytes
make contact through interruptions in the capillary basement mem-
brane known as “peg and socket” junctions [60] (Fig. 4). These are cy-
toplasmic invaginations that may contain tight, gap and adherens
junctions as well as integrins [60,61]. It is the discontinuous nature of
the basementmembrane, and the peg and socket that allows an intimate
signaling relationship to exist between endothelial cells and pericytes;
onewhich includes electrical signaling as well as receptor-ligand signal-
ing [62].
Although no truly speciﬁc biomarkers for pericytes have been
detected, they do express the vascular growth factors angiopoietin-1
and vascular growth factor (VEGF), and the developmentally important
PDGF receptorsα and β [30,63]. They also express a number of markers
associated with mesenchymal stem cells, including CD44, CD73, CD105
and CD146 [64]. Of note is that cells continue to express PDGFRβ after
they become myoﬁbroblasts, and that, conversely, pericytes may ex-
press collagen I transcript even in healthy tissue [21]. In addition,
pericytes variably express a number of neurological markers including
NG2, synaptopodin, GFAP, and p75 nerve growth factor receptor
(NFGR).
A recent study in the kidney has identiﬁed two novel pericyte
markers, ADAMTS1 and TIMP3 (respectively: a disintegrin and
metalloprotease with thrombospondin motifs-1; and tissue inhibitor
of metalloproteinase 3), that may have functional implications in the
transition of pericytes to myoﬁbroblasts. In ex vivo experiments where-
by cultured pericytes stabilized endothelial tubular networks (essentially,
a reconstituted capillary), TIMP3 was found to promote stabilization,
whereas ADAMTS1 impeded it. As well as validating two potential
pericyte markers, this study elucidates the importance of the pericyte to
vascular stability [65].
6. Pericyte interactions with the microvasculature
As aforementioned, confocal microscopy has allowed high-resolution
images of the pericyte detaching from the capillary bed [20]. What is
clear from a recent study is that this detachment is a function of
deregulated pericyte–endothelial cell signaling [30]. Pericytes express
PDGFR-β on their cell-surface and secrete VEGF; endothelial cells, in re-
ciprocation, express VEGF receptor 2 on their cell-surface, and secrete
PDGF. When either of these receptors is blocked, both ﬁbrosis and capil-
lary rarefaction are ameliorated during kidney injury. Interestingly, dur-
ing disease progression, pericytes switch from producing angiogenic
isoform VEGF164, and begin secreting dys-angiogenic VEGF120 and
VEGF188 isoforms.Moreover, blockade of either the VEGF or PDGF recep-
tor pathway results in a commensurate break on pericyte differentiation
and proliferation, but VEGFR2 blockade also results in attenuated macro-
phage recruitment [30]. This result tantalizingly hints at a new functional
nexus between inﬂammation, capillary and ﬁbrotic injury: a paradigm
that is likely to growwith our understanding of pericyte biology. In a fur-
ther example of cross-talk, endothelial cells recruit pericytes during an-
giogenesis through paracrine release of PDGF-BB and heparin binding
epidermal growth factor (HB-EGF) [66].
The biomechanics, and the signal transduction pathways, involved
in pericyte detachment are yet to be fully elucidated. It is likely to in-
volve a complex interplay between integrins, focal adhesion kinase
(FAK), p21 protein activated kinase (PAK) and the actin–myosin cyto-
skeleton. Unsurprisingly, given its well-established effects on the cy-
toskeleton, the Rho-family of GTPase proteins has been shown to play
a role in (retinal) pericyte contractibility, as well as paracrine effects
upon endothelial cells [67]. However, this study relied on indirect de-
lineation of the Rho pathway by inhibiting downstream Rho-kinase
(ROCK1/2), and overexpressing Rho-mutants (which do not
968 N. Hutchison et al. / Biochimica et Biophysica Acta 1832 (2013) 962–971
969N. Hutchison et al. / Biochimica et Biophysica Acta 1832 (2013) 962–971discriminate between, for example, RhoA, RhoB and RhoC). The Rho
family is large, with at least twenty mammalian isoforms, and a
ﬁne-interplay between them determines cell behavior [68].
The exact nature of pericyte-CBM, and pericyte–endothelial cell
co-ordinations requires further study (Fig. 4). However, it is known
that pericyte recruitment by endothelial cells is accompanied by in-
creased expression of integrin types α5β1, α3β1, α6β1, and α1β1,
which bind ﬁbronectin, nidogens, laminin isoforms, and collagen type
IV [69].
7. Epithelial cell signaling in ﬁbrogenesis
Recent fate-mapping studies indicate that whereas epithelial-to-
mesenchymal transition (EMT) can occur in vitro, it does not contribute
to the appearance ofmyoﬁbroblasts in vivo [19,20,34]. However, studies
unequivocally show that the injured epithelium alone can directly trig-
ger ﬁbrogenesis in many organs. For example in adult kidney injury, in
addition to endothelial cells, injured epithelial cells produce PDGF and
TGFβ1, and the TGFβ1 activator integrinαvβ6 is restricted to kidney ep-
ithelium [70–74]. Increased epithelial expression of TGFβ1 is accompa-
nied by activation of intracellular canonical (Smad) and non-canonical
(PAK2, c-Abl, Akt, tuberin and mTorC1) signaling pathways in the epi-
thelium itself [75,76]. Blocking TGFβ1 and its downstream effectors
can attenuate kidney injury and ﬁbrosis [75–78], whereas transgenic
overexpression of TGFβ1 in kidney epithelial cells is sufﬁcient to trigger
interstitial kidneyﬁbrosis in the absence of any evidence of EMT [35,79].
Moreover, a recent study demonstrated that TGFβ1 released from in-
jured renal epithelium can activate the canonical Smad pathway in
pericytes, leading to their activation to myoﬁbroblasts [80]. Therefore,
injured epithelium is a source of ligands that are important factors in
driving ﬁbrogenesis. In addition, epithelial cells are signiﬁcant sources
of proinﬂammatory cytokines and chemokines, which contribute di-
rectly to ﬁbrogenesis in several organs [81].
8. Therapeutic approaches to the treatment of ﬁbrosis: targeting
pericytes and myoﬁbroblasts
Although ﬁbrosis was at one time considered a progressive and irre-
versible disease, data from animal models and human studies have pro-
vided clear evidence that ﬁbrosis can be at least partially reversible.
There is now some clinical evidence that ﬁbrosis can regress in a variety
of chronic liver diseases, observed either on cessation of the cause of
liver injury or treatment of the underlying disease; but the evidence is
limited or debated, frequently being based on small, retrospective co-
hort studies [82]. Regression of ﬁbrosis in chronic kidney disease has
also been achieved in experimental models following therapy with
renin–angiotensin system blockers [83]. These results, however, con-
trast with large-scale human studies that observed at best, renin angio-
tensin system blockade slows the rate of loss of renal function [84]. The
terms “reversal or reversibility” are often used to imply a complete res-
toration of normal architecture after the establishment of ﬁbrosis. A bet-
ter term instead would be “regression” of ﬁbrosis, indicating that the
ﬁbrosis content is less than earlier, without quantifying the extent of re-
gression or suggesting that the histology has returned completely to
normal.
To date, despite the enormous unmetmedical need for an effective
antiﬁbrotic agent, the majority of the potential drug products are stillFig. 4. Pericyte localization in the microvasculature. (A) Schematic depicting pericyte–endoth
microvasculature where they partially cover capillary endothelial cells. Pericytes have long m
membrane (CBM), which they share with endothelial cells. The CBM is frequently incomple
nections can form, including cytoplasmic invaginations known as peg & socket processes. It i
endothelial cells and pericytes, including PDGF–VEGF signaling. (B) In response to injury or
ical ﬁbrillar matrix. In the process, CBM is degraded and endothelial cells lose the support of p
signals). (C) Pericyte detachment has two major consequences. Firstly, the injured organ is
schematically by a reduction in their number). The resulting hypoxia in the organ can fee
laminins by pericytes/myoﬁbroblasts distorts parenchymal tissue architecture (for example
tissues, impeding their normal functions.undergoing clinical trials to prove their efﬁcacy and safety. Among the
potential drugs that target receptors expressed by myoﬁbroblasts or
growth factors released by them, pirfenidone is an orally active p38
kinase inhibitor that reduces the activity of TGF-β1 and TNF-α in
vitro. It is the ﬁrst anti-ﬁbrotic drug to be approved for the treatment
of idiopathic pulmonary ﬁbrosis, both in Europe and Japan (but not in
the USA) [85]. Therapeutic TGF-β1-neutralizing antibodies have also
been developed and tested on a mouse model of lung ﬁbrosis [86].
Fresolimumab (GC1008), a human monoclonal antibody that inacti-
vates all forms of TGF-β1 is undergoing clinical trials by Genzyme as
a treatment for patients with focal segmental glomerulosclerosis
[87]; its application is also explored in systemic sclerosis and idio-
pathic pulmonary ﬁbrosis.
Ongoing trials are investigating the potential of imatinib mesylate,
a small-molecule tyrosine kinase inhibitor marketed by Novartis,
which inhibits signaling of PDGFRs (and also c-Abl and c-kit), as a
treatment for nephrogenic systemic ﬁbrosis [88], and newer generation
of tyrosine kinase inhibitors in the treatment of pulmonary ﬁbrosis. A
fully humanized neutralizing monoclonal antibody, targeting the CTGF
protein which is known to be an important pro-ﬁbrotic factor both as
a downstream effector and cooperative mediator of TGFβ1 action, is
used in clinical trials for the treatment of diabetic nephropathy [89] as
well as idiopathic pulmonary ﬁbrosis by Fibrogen. However, there is ev-
idence that other molecules targeting more recently identiﬁed path-
ways are making progress in the clinic. Readers are directed to a
recent excellent review discussing extensively these drugs [90].9. Conclusion
In all cases of ﬁbrosis, pathogenic myoﬁbroblasts are derived pri-
marily from residentmesenchymal cells. These cells are found in almost
all tissues, with a varied nomenclature accordingly. When localized to
the microvasculature, they are known as pericytes. All resident mesen-
chymal cells respond to injury by activating dormant genes from their
development, such asαSMA and NG2, andmigrating into the site of in-
jury. Here they begin depositing the collagenous ﬁbers and laminins,
which characterize ﬁbrosis. Such a view –with one cell-type differenti-
ating into myoﬁbroblasts in response to injury – presents us with the
prospect of a uniﬁed model of ﬁbrogenesis across the entire body.Conﬂict of interest
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